Physician profile
Daniel Koh
NPI 1306946033
$1,893.11
in general payments reported to CMS, 2019-2025
26 companies · $491 in 2025
The $491 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $510 · 2020: $35.38 · 2021: $98.05 · 2022: $465 · 2023: $63.26 · 2024: $229 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $710 · Education: $73.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $710.08 |
| Education | $73.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $350.00 | 2019-2022 | |
| Novocure Gmbh | $250.00 | 2022 | |
| Abbott Laboratories | $142.91 | 2025 | Esprit |
| Novartis Pharmaceuticals Corporation | $124.95 | 2023-2025 | |
| Astellas Pharma US INC | $119.76 | 2019-2020 | |
| Baxter Healthcare | $107.14 | 2025 | Floseal |
| Progenics Pharmaceuticals, INC. | $104.06 | 2024 | |
| Incyte Corporation | $98.05 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $88.05 | 2019-2025 | Enhertu, Imfinzi |
| Clovis Oncology, INC. | $74.99 | 2019 | |
| Scpharmaceuticals INC. | $54.70 | 2024 | |
| Pfizer INC. | $53.78 | 2019-2025 | |
| Genentech USA, INC. | $37.78 | 2019-2023 | Venclexta |
| Conmed Corporation | $35.71 | 2025 | Airseal |
| Pharmacyclics LLC, An Abbvie Company | $35.49 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $30.81 | 2019-2024 | |
| Glaxosmithkline, LLC. | $28.55 | 2025 | Blenrep, Ojjaara |
| Kyowa Kirin, INC. | $23.06 | 2019 | |
| Eisai INC. | $20.12 | 2025 | |
| Array Biopharma INC | $19.98 | 2023 | |
| Merck Sharp & Dohme LLC | $19.83 | 2019 | |
| Karyopharm Therapeutics INC. | $15.61 | 2020 | |
| Celgene Corporation | $15.33 | 2022 | |
| Rigel Pharmaceuticals, INC. | $15.28 | 2024 | Tavalisse, Rezlidhia |
| Teva Pharmaceuticals USA, INC. | $15.25 | 2019 | |
| Janssen Biotech, INC. | $11.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Koh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.